120 related articles for article (PubMed ID: 27608899)
61. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.
Li W; Zhang J; Guo L; Chuai S; Shan L; Ying J
J Thorac Oncol; 2017 Jan; 12(1):94-101. PubMed ID: 27614248
[TBL] [Abstract][Full Text] [Related]
62. Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma.
Ogata D; Yanagisawa H; Suzuki K; Oashi K; Yamazaki N; Tsuchida T
Med Oncol; 2016 Oct; 33(10):116. PubMed ID: 27613162
[TBL] [Abstract][Full Text] [Related]
63. Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis.
Sehm T; Rauh M; Wiendieck K; Buchfelder M; Eyüpoglu IY; Savaskan NE
Oncotarget; 2016 Nov; 7(46):74630-74647. PubMed ID: 27612422
[TBL] [Abstract][Full Text] [Related]
64. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
65. Factors Influencing Clinicians' Choice of Adjuvant S-1 versus Capecitabine plus Oxaliplatin after Curative Gastrectomy in Patients with Gastric Cancer.
Lee HY; Hwang IG; Park SE; Kim MJ; Park SH; Kang JH; Kim YS; Oh SY; Won YW; Lee SI; Ji JH; Chi KC
J Cancer; 2016; 7(12):1711-1715. PubMed ID: 27698908
[No Abstract] [Full Text] [Related]
66. Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Pinto C; Antonuzzo L; Porcu L; Aprile G; Maiello E; Masi G; Petrelli F; Scartozzi M; Torri V; Barni S
Clin Colorectal Cancer; 2017 Jun; 16(2):e61-e72. PubMed ID: 27687553
[TBL] [Abstract][Full Text] [Related]
67. Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells.
Wang YQ; Shen AJ; Sun JY; Wang X; Liu HC; Zhang MM; Chen DQ; Xiong B; Shen JK; Geng MY; Zheng M; Ding J
Acta Pharmacol Sin; 2016 Dec; 37(12):1587-1596. PubMed ID: 27616574
[TBL] [Abstract][Full Text] [Related]
68. Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement.
Zhang L; Jiang T; Zhao C; Li W; Li X; Zhao S; Liu X; Jia Y; Yang H; Ren S; Zhou C
Oncotarget; 2016 Nov; 7(46):75145-75154. PubMed ID: 27738334
[TBL] [Abstract][Full Text] [Related]
69. Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial.
Chu MP; Hecht JR; Slamon D; Wainberg ZA; Bang YJ; Hoff PM; Sobrero A; Qin S; Afenjar K; Houe V; King K; Koski S; Mulder K; Hiller JP; Scarfe A; Spratlin J; Huang YJ; Khan-Wasti S; Chua N; Sawyer MB
JAMA Oncol; 2017 Jun; 3(6):767-773. PubMed ID: 27737436
[TBL] [Abstract][Full Text] [Related]
70. Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib.
Lacy SA; Miles DR; Nguyen LT
Clin Pharmacokinet; 2017 May; 56(5):477-491. PubMed ID: 27734291
[TBL] [Abstract][Full Text] [Related]
71. Acute Toxicity and Tumor Response in Locally Advanced Rectal Cancer After Preoperative Chemoradiation Therapy With Shortening of the Overall Treatment Time Using Intensity-Modulated Radiation Therapy With Simultaneous Integrated Boost: A Phase 2 Trial.
But-Hadzic J; Anderluh F; Brecelj E; Edhemovic I; Secerov-Ermenc A; Hudej R; Jeromen A; Kozelj M; Krebs B; Oblak I; Omejc M; Vogrin A; Velenik V
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1003-1010. PubMed ID: 27727065
[TBL] [Abstract][Full Text] [Related]
72. Early
De Rosa V; Iommelli F; Monti M; Mainolfi CG; Fonti R; Del Vecchio S
EJNMMI Res; 2016 Dec; 6(1):74. PubMed ID: 27726115
[TBL] [Abstract][Full Text] [Related]
73. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
Rochlitz C; Bigler M; von Moos R; Bernhard J; Matter-Walstra K; Wicki A; Zaman K; Anchisi S; Küng M; Na KJ; Bärtschi D; Borner M; Rordorf T; Rauch D; Müller A; Ruhstaller T; Vetter M; Trojan A; Hasler-Strub U; Cathomas R; Winterhalder R;
BMC Cancer; 2016 Oct; 16(1):780. PubMed ID: 27724870
[TBL] [Abstract][Full Text] [Related]
74. Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer.
Li H; Stokes W; Chater E; Roy R; de Bruin E; Hu Y; Liu Z; Smit EF; Heynen GJ; Downward J; Seckl MJ; Wang Y; Tang H; Pardo OE
Cell Discov; 2016; 2():16031. PubMed ID: 27721983
[TBL] [Abstract][Full Text] [Related]
75. Combination Chemotherapy of Mitomycin C and Methotrexate Was Effective on Metastatic Breast Cancer Resistant to Eribulin, Vinorelbine, and Bevacizumab after Anthracycline, Taxane, and Capecitabine.
Tanabe M
Case Rep Oncol; 2016; 9(2):422-426. PubMed ID: 27721762
[TBL] [Abstract][Full Text] [Related]
76. A phase I study of nedaplatin, pemetrexed and thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinoma.
Lu Y; Gu W; Deng J; Yang H; Yang W
BMC Cancer; 2016 Oct; 16(1):775. PubMed ID: 27717315
[TBL] [Abstract][Full Text] [Related]
77. Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.
Zhao H; Nolley R; Chan AMW; Rankin EB; Peehl DM
Cancer Biol Ther; 2017 Nov; 18(11):863-871. PubMed ID: 27715452
[TBL] [Abstract][Full Text] [Related]
78. The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials.
Huang J; Zhang Y; Sheng J; Zhang H; Fang W; Zhan J; Zhou T; Chen Y; Liu L; Zhang L
Onco Targets Ther; 2016; 9():5867-5874. PubMed ID: 27713640
[TBL] [Abstract][Full Text] [Related]
79. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.
Murai J; Feng Y; Yu GK; Ru Y; Tang SW; Shen Y; Pommier Y
Oncotarget; 2016 Nov; 7(47):76534-76550. PubMed ID: 27708213
[TBL] [Abstract][Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
